Gland Pharma Limited (NSE:GLAND)
India · Delayed Price · Currency is INR 1,978.50
-86.30 (-4.18%)
Aug 1, 2025, 3:30 PM IST
ATSG Revenue
In the fiscal year ending March 31, 2025, Gland Pharma had annual revenue of 56.17B INR, down -0.85%. Gland Pharma had revenue of 14.25B in the quarter ending March 31, 2025, a decrease of -7.32%.
Revenue
56.17B
Revenue Growth
-0.85%
P/S Ratio
5.80
Revenue / Employee
13.10M
Employees
4,286
Market Cap
325.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 56.17B | -482.18M | -0.85% |
| Mar 31, 2024 | 56.65B | 20.40B | 56.29% |
| Mar 31, 2023 | 36.25B | -7.76B | -17.64% |
| Mar 31, 2022 | 44.01B | 9.38B | 27.08% |
| Mar 31, 2021 | 34.63B | 8.30B | 31.51% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 93.60B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 232.42B |
| Fortis Healthcare | 77.86B |
| Aurobindo Pharma | 317.24B |
Gland Pharma News
- 21 days ago - Gland Pharma gets GMP certification for Pashamylaram facility from Danish Medicines Agency - Business Upturn
- 5 weeks ago - Gland Pharma gets EIR from US FDA for Visakhapatnam JNPC facility - Business Upturn
- 6 weeks ago - Top stocks to buy today: Stock recommendations for June 19, 2025 - check list - The Times of India
- 2 months ago - Top stocks to watch today, June 5: Gland Pharma, HAL, Newgen Software, NTPC Green, Angel One and more - Business Upturn
- 2 months ago - Gland Pharma gets USFDA nod for Angiotensin II Acetate Injection, secures 180-day exclusivity - Business Upturn
- 2 months ago - Gland Pharma shares rise over 3% following Q4 Results - Business Upturn
- 2 months ago - Gland Pharma share price: Nomura sees 4% upside, maintains neutral on soft Q4 and cautious outlook - Business Upturn
- 2 months ago - Brokerage radar: Hindalco, BEL, Dixon, Zydus, Gland Pharma in focus after Q4; target prices revised - Business Upturn